News
Be the first to know what’s happening at Gene Therapy Initiative! Subscribe to our quarterly newsletter to stay informed about the latest updates, special announcements, upcoming events, and exclusive news.
Be the first to know what’s happening at Gene Therapy Initiative! Subscribe to our quarterly newsletter to stay informed about the latest updates, special announcements, upcoming events, and exclusive news.
The second pediatric patient has officially received the stem cell and gene therapy treatment at UC San Diego, marking a historic milestone not only for our foundation, but for the entire scientific community.
The designation joins UC San Diego School of Medicine and Rady Children’s with a national network spanning more than 150 academic medical centers, research institutions and children’s hospitals working together to advance rare disease care and research in Southern California and nationwide.
Farah Sheikh, PhD, professor of medicine at the University of California San Diego School of Medicine, was recently honored by the International Society for Heart Research (ISHR) North American Section with the 2026 Innovator Award. She delivered the Innovator Award Lecture at the ISHR North American Section Annual Meeting in Minneapolis.
A harmful protein called TDP-43 plays a major role in brain diseases like frontotemporal dementia and is also found in many people with Alzheimer’s disease An experimental gene therapy developed by UC San Diego researchers helped protect brain cells from that damage
Six professors from the University of California San Diego have been named Senior Members of the National Academy of Inventors (NAI) in recognition of their outstanding achievements in innovation. The UC San Diego honorees in NAI’s 2026 class of Senior Members are Omar Akbari, Brian P. Head (GTI Seed Grant Recipient), Abdoulaye Ndao, Kenneth Vecchio, Edward Wang and Yunde Zhao.
Reporting early clinical results of a first-of-its-kind hematopoietic stem cell–based gene therapy for cystinosis, a rare inherited lysosomal storage disorder. In a Phase I/II trial at the University of California, San Diego, the investigational therapy demonstrated sustained reductions in cystine levels and stable organ function in most adult patients with advanced disease, supporting continued development and ongoing evaluation in pediatric patients.
Funding supports safety studies, manufacturing and clinical planning needed before applying to test the treatment in patients.
Two projects explore the rare Pitt-Hopkins and Rett syndromes using organoids that mimic organs.
UC San Diego is a world leader in gene therapy research — one child’s wish helped them get there.
The GTI is built on the belief that collaboration drives impact. A recent feature from UC San Diego Today highlights this mission in action, sharing how a GTI-facilitated connection brought together biotech entrepreneur Gavenraj Singh Sodhi and GTI co-director Dr. Alysson Muotri. Their shared interests have evolved into an exploration of brain organoid technology as a potential pathway for identifying treatments for rare diseases, including those affecting Sodhi’s daughter, Maddie.
The inaugural symposium brought together experts, funders, and patient advocates to highlight cutting-edge gene therapy advances and the power of collaboration.
Betty Cabrera, GTI Director of Research Engagement, participated as a panelist at the RARE Drug Development Symposium in Philadelphia, where discussions centered on innovative commercial and non-profit funding models for preclinical drug development. During the session, GTI showcased how UC San Diego researchers are leveraging rare disease research to drive advances in more prevalent disease.